| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| Other Sizes |
| Targets |
BTK (IC50 = 0.7 nM)
|
|---|---|
| ln Vitro |
PRN2246 inhibits both Fc receptor activation (IC50=166 and 9.6 nM for FcεR and FcγR) and BCR-mediated immune cell activation (IC50=10 nM) [2]. With an IC50 of 157 nM, PRN2246 targets small molecule FcγR activation via persistent port BTK [2].
|
| ln Vivo |
PRN2246 (1-5 mg/kg; po, qd, for 28 days) exhibits dose-induced protection in myelin oligodendrocyte glycoprotein (MOG)-induced experimental autoimmune encephalitis (EAE) model [2].
|
| References |
|
| Additional Infomation |
Tolebrutinib is a small-molecule Bruton's tyrosine kinase (BTK) inhibitor with high oral bioavailability, blood-brain barrier penetration, and selective activity, possessing potential immunomodulatory and anti-inflammatory activities. After oral administration, Tolebrutinib crosses the blood-brain barrier and inhibits BTK activity in the peripheral and central nervous systems (CNS). This prevents activation of the B cell antigen receptor (BCR) signaling pathway, thereby suppressing immune activation and inflammatory responses. Inhibition of BTK activity also blocks inflammatory signaling in microglia of the CNS, thereby suppressing immune activation, neuroinflammation, and neurodegeneration. BTK is a cytoplasmic tyrosine kinase belonging to the Tec kinase family, playing a crucial role in the development, activation, signaling, proliferation, and survival of B lymphocytes. In addition to B cells, BTK is also expressed in innate immune cells such as macrophages and microglia, playing a vital role in regulating inflammatory signaling in microglia.
|
| Molecular Formula |
C26H25N5O3
|
|---|---|
| Molecular Weight |
455.5084
|
| Exact Mass |
455.195
|
| CAS # |
1971920-73-6
|
| PubChem CID |
124111565
|
| Appearance |
Off-white to light yellow solid powder
|
| Density |
1.3±0.1 g/cm3
|
| Boiling Point |
644.4±65.0 °C at 760 mmHg
|
| Flash Point |
343.5±34.3 °C
|
| Vapour Pressure |
0.0±1.9 mmHg at 25°C
|
| Index of Refraction |
1.680
|
| LogP |
1.76
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
5
|
| Heavy Atom Count |
34
|
| Complexity |
749
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
C=CC(=O)N1CCC[C@H](C1)N2C3=C(C(=NC=C3)N)N(C2=O)C4=CC=C(C=C4)OC5=CC=CC=C5
|
| InChi Key |
KOEUOFPEZFUWRF-LJQANCHMSA-N
|
| InChi Code |
InChI=1S/C26H25N5O3/c1-2-23(32)29-16-6-7-19(17-29)30-22-14-15-28-25(27)24(22)31(26(30)33)18-10-12-21(13-11-18)34-20-8-4-3-5-9-20/h2-5,8-15,19H,1,6-7,16-17H2,(H2,27,28)/t19-/m1/s1
|
| Chemical Name |
4-amino-3-(4-phenoxyphenyl)-1-[(3R)-1-prop-2-enoylpiperidin-3-yl]imidazo[4,5-c]pyridin-2-one
|
| Synonyms |
Tolebrutinib; 1971920-73-6; PRN2246; SAR442168; Tolebrutinib [INN];
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~219.53 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (5.49 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (5.49 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (5.49 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.1953 mL | 10.9767 mL | 21.9534 mL | |
| 5 mM | 0.4391 mL | 2.1953 mL | 4.3907 mL | |
| 10 mM | 0.2195 mL | 1.0977 mL | 2.1953 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
